Chai Discovery Eli Lilly AI drug discovery: A $1.3 billion leap for biotech
Chai Discovery lands a $1.3B valuation and partners with Eli Lilly for AI-powered drug discovery. Explore the OpenAI-backed startup's journey and its Chai-2 algorithm.
In just over 12 months, Chai Discovery has gone from a stealthy startup to a $1.3 billion heavyweight. By securing $130 million in Series B funding this December, the company is positioning itself as the "CAD suite" for molecular design, aiming to replace expensive trial-and-error with precision AI.
The Chai Discovery Eli Lilly AI drug discovery deal
Last Friday, the startup announced a milestone partnership with pharmaceutical giant Eli Lilly. Lilly will utilize Chai’s flagship algorithm, Chai-2, to design therapeutic antibodies—the specialized proteins used to combat complex diseases. This collaboration isn't just a pilot; it's a strategic move to push the frontier of how generative AI can build better molecules from scratch.
Born from the OpenAI inner circle
Chai’s rapid ascent is no accident. Co-founders Josh Meier and Jack Dent have deep ties to OpenAI and its CEO, Sam Altman. Meier, a former OpenAI researcher, was encouraged by Altman years ago to start a proteomics firm. OpenAI eventually became an early investor, even providing office space in San Francisco during the company's infancy. Meier’s previous work at Facebook on the ESM1 protein-language model serves as the technological precursor to Chai’s current innovations.
| Entity | Partnership Role | Value/Focus |
|---|---|---|
| Eli Lilly | Strategic Partner | Antibody Design |
| Nvidia | Co-innovation Lab | $1 Billion investment |
| OpenAI | Seed Investor | Early support & space |
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
Tinder now rewards users who scan their irises at a World orb with free in-app boosts. As AI agents flood dating apps, 'being human' is becoming a verified status — and a business model.
OpenAI CEO Sam Altman's San Francisco residence was attacked twice in three days — first a Molotov cocktail, then a shooting. What does this say about tech power, public anger, and the real-world risks facing AI leaders?
California startup R3 Bio quietly pitched investors on 'brainless human clones' as backup bodies—beyond its public story of nonsentient organ sacks for drug testing. A deep dive into biotech's most ethically charged frontier.
Sam Altman thanked developers for writing code the hard way. The same week, Amazon cut 16,000 jobs. What does gratitude mean when the grateful party built the replacement?
Tinder now rewards users who scan their irises at a World orb with free in-app boosts. As AI agents flood dating apps, 'being human' is becoming a verified status — and a business model.
OpenAI CEO Sam Altman's San Francisco residence was attacked twice in three days — first a Molotov cocktail, then a shooting. What does this say about tech power, public anger, and the real-world risks facing AI leaders?
California startup R3 Bio quietly pitched investors on 'brainless human clones' as backup bodies—beyond its public story of nonsentient organ sacks for drug testing. A deep dive into biotech's most ethically charged frontier.
Sam Altman thanked developers for writing code the hard way. The same week, Amazon cut 16,000 jobs. What does gratitude mean when the grateful party built the replacement?
Thoughts
Share your thoughts on this article
Sign in to join the conversation